Imagen de Portada

Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ib trial

Guardado en:
Publicado en:Signal Transduction and Targeted Therapy vol. 9, no. 1 (2024), p. 318
Autor principal: Liu, Jiayong
Otros Autores: Wang, Xuan, Li, Zhongwu, Gao, Shunyu, Mao, Lili, Dai, Jie, Li, Caili, Cui, Chuanliang, Chi, Zhihong, Sheng, Xinan, Lai, Yumei, Tan, Zhichao, Lian, Bin, Tang, Bixia, Yan, Xieqiao, Li, Siming, Zhou, Li, Wei, Xiaoting, Li, Juan, Guo, Jun, Si, Lu
Publicado:
Nature Publishing Group
Materias:
Chemokines
Adjuvants
Oncolysis
Lymphocytes
Cytokines
Melanoma
Antitumor activity
Response rates
Tumor-infiltrating lymphocytes
Surgery
PD-1 protein
Patients
Adjuvant therapy
Acceso en línea:Citation/Abstract
Full Text - PDF
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Resumen:Neoadjuvant PD-1 inhibitor is promising in cutaneous melanoma but remains unknown in acral melanoma (AM). This phase Ib trial study (Clinicaltrials.gov NCT04197882) assessed the efficacy and safety of the combination of neoadjuvant oncolytic virus orienX010 (ori) and anti-PD-1 toripalimab (tori) for resectable AM. Thirty patients of stage III/IV received neoadjuvant therapy of ori and tori for 12 weeks before surgery, followed by adjuvant treatment with tori for 1 year. Primary endpoints were radiographic and pathological response rates, with secondary endpoints of 1- and 2-year recurrence-free survival (RFS) rates, event-free survival (EFS) rates, and safety. Twenty-seven completed surgery and tori adjuvant treatment and median follow-up was 35.7 months. Radiographic and pathological response rates were 36.7% and 77.8%, with complete response rates of 3.3% and 14.8%, 1- and 2-year RFS rates of 85.2% and 81.5%, and 1- and 2-year EFS rates of 83% and 73%, respectively. Adverse events occurred in all patients, mainly grade 1–2. There was no correlation between PET/CT evaluation and pathological response or progression-free survival/overall survival. Patients with pathological response showed tumor beds with high tertiary lymphoid structures (TLSs) and tumor-infiltrating lymphocytes (TILs). Cytokines and chemokines analysis showed the combination therapy significantly increases the secretion of proinflammatory cytokines and chemokines in both responders and non-responders. Therefore, neoadjuvant ori and tori demonstrated promising antitumor activity with high response rates and high 2-year RFS/EFS for AM with acceptable tolerability.
ISSN:2095-9907
2059-3635
DOI:10.1038/s41392-024-02029-2
Fuente:Health & Medical Collection